Core Insights - Neurocrine Biosciences, Inc. announced significant variability in glucocorticoid treatment regimens for patients with classic congenital adrenal hyperplasia (CAH), highlighting the complexity of managing the condition over a lifetime [1][2][4] Treatment Patterns and Findings - The CAHtalog registry analysis included data from 98 patients, revealing that 88.9% experienced at least one health state change, with 58.7% undergoing three or more changes during a median observation period of 8.6 years [3][5] - Most patients were exposed to supraphysiologic doses of glucocorticoids and/or elevated androstenedione levels at least once, indicating ongoing challenges in achieving long-term disease control [8][10] Implications for Future Treatment - The analysis emphasizes the need for advanced therapeutic options to manage CAH effectively, as current glucocorticoid treatments often require high doses that can lead to significant complications [6][12] - CRENESSITY (crinecerfont), a new treatment option, aims to reduce ACTH and adrenal androgens through a non-glucocorticoid mechanism, potentially allowing for more physiologic glucocorticoid dosing [14][15]